首页>投融资
Mirvie
捐赠/众筹/授予
Mirvie is a medical diagnostic platform designed to make pregnancy safe by delivering insights to moms and families. The company's platform offers predictive tests and facilitates therapeutic approaches for pregnancy management, enabling medical practitioners to identify at-risk pregnancies and facilitating correctiveIn May 2022, Mirvie raised $90 million to date following the close of its Series B funding led by Decheng Capital
基本信息
-
公司全称Mirvie
-
类型孕期血液测试平台
-
产业领域器械/设备、试剂/耗材、检测服务
-
公司人数15人以下
-
地址820 Dubuque Avenue SOUTH SAN FRANCISCO CALIFORNIA 94080; US; Telephone: +16507416510;
-
联系电话650-741-6510
-
邮箱studies@mirvie.com
-
成立时间2018-01-01
投融资
-
2023-08-02捐赠/众筹/授予460万美元Bill and Melinda Gates Foundation
-
2022-05-17B轮6000万美元GVGeneral CatalystKhosla VenturesBlackRockComerica BankMayfield Fund德诚资本Foresite Capital
相关投融资企业
PreA轮
IRUBIS开发了一种生物过程监测仪器，旨在使中红外光谱对生物反应器的在线控制成为标准。该公司的仪器用于代谢物监测的上下游生物处理，用于聚集研究，污染物检测，目标蛋白和辅料的检测，借助MIR光谱传感器和机器学习评估软件，使实验室研究人员能够实现对血液样本和相关含水流体的营养浓度的连续监测和控制。
B轮
上海汇像始终坚持将人工智能技术与检验检测技术相融合，致力于为生物化学，医疗医药及安全检验检测提供领先的实验室自动化·智能化综合解决方案，产品范围涵盖从食品安全、药品安全到生命科学领域的智能机器人工作站系统、全流程检验检测实验室自动化、智能化整合系统以及配套自动化·智能化仪器设备及相关耗材等。
捐赠/众筹/授予
Mirvie is a medical diagnostic platform designed to make pregnancy safe by delivering insights to moms and families. The company's platform offers predictive tests and facilitates therapeutic approaches for pregnancy management, enabling medical practitioners to identify at-risk pregnancies and facilitating correctiveIn May 2022, Mirvie raised $90 million to date following the close of its Series B funding led by Decheng Capital
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息